Agenus’ (AGEN) “Buy” Rating Reiterated at B. Riley Financial

B. Riley Financial reissued their buy rating on shares of Agenus (NASDAQ:AGEN) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $16.00 price objective on the biotechnology company’s stock, up from their previous price objective of $14.00.

A number of other research analysts have also weighed in on the company. Chardan Capital reaffirmed a “buy” rating on shares of Agenus in a report on Thursday, October 22nd. Rodman & Renshaw began coverage on shares of Agenus in a report on Monday, September 28th. They issued a “buy” rating and a $19.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $25.00 price objective (down from $30.00) on shares of Agenus in a research report on Tuesday, August 11th. Weiss Ratings upgraded shares of Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Finally, Wall Street Zen cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

Agenus Price Performance

Agenus stock opened at $7.22 on Monday. The firm has a market capitalization of $326.70 million, a P/E ratio of 10.94 and a beta of 1.53. Agenus has a one year low of $2.71 and a one year high of $10.31. The business has a fifty day moving average price of $7.42 and a 200-day moving average price of $5.06.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.30. The company had revenue of $31.49 million for the quarter, compared to analyst estimates of $28.20 million. Agenus had a negative return on equity of 27.16% and a net margin of 22.10%. Sell-side analysts expect that Agenus will post -0.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agenus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Globeflex Capital L P bought a new position in Agenus in the 2nd quarter worth about $1,281,000. Bank of America Corp DE raised its holdings in shares of Agenus by 796.7% in the 1st quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock valued at $397,000 after acquiring an additional 105,536 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Agenus in the 2nd quarter valued at about $311,000. HighTower Advisors LLC bought a new stake in shares of Agenus during the 3rd quarter valued at about $574,000. Finally, State of Wyoming bought a new stake in shares of Agenus during the 3rd quarter valued at about $225,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc. is a biotechnology company focused on developing immunotherapies for cancer. Its research and development programs use approaches such as antibody treatments, cancer vaccines, immune-system adjuvants and cell therapies. The company’s clinical-stage pipeline includes botensilimab, an investigational anti-CTLA-4 antibody, and balstilimab, an investigational anti-PD-1 antibody. Agenus is studying these therapies, including in combination, for potential use against several types of cancer.